BACKGROUND: A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) describe the toxicities of this regimen; and (iii) evaluate the plasma pharmacokinetic parameters and extent of PARP inhibition in peripheral blood mononuclear cells (PBMCs) following veliparib. METHODS: TMZ was given once daily and veliparib twice daily for 5 days every 28 days. Veliparib concentrations and poly(ADP-ribose) (PAR) levels in PBMCs were measured on days 1 and 4. Analysis of pharmacokinetic and PBMC PAR levels were performed twice during study conduct to rationally guide dose modifications and to determine biologically optimal MTD/RP2D. RESULTS: Twenty-nine evaluable patients were enrolled. Myelosuppression (grade 4 neutropenia and thrombocytopenia) were dose limiting. The RP2Ds are veliparib 25 mg/m(2) b.i.d. and TMZ 135 mg/m(2)/d. Only 2 out of 12 patients treated at RP2Ds experienced dose-limiting toxicities. Although no objective response was observed, 4 patients had stable disease >6 months in duration, including 1 with glioblastoma multiforme and 1 with ependymoma. At the RP2D of veliparib, pediatric pharmacokinetic parameters were similar to those in adults. CONCLUSIONS: Veliparib and TMZ at the RP2D were well tolerated in children with recurrent brain tumors. A phase I/II trial to evaluate the tolerability and efficacy of veliparib, TMZ, and radiation in children with newly diagnosed brainstem gliomas is in progress.
BACKGROUND: A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) describe the toxicities of this regimen; and (iii) evaluate the plasma pharmacokinetic parameters and extent of PARP inhibition in peripheral blood mononuclear cells (PBMCs) following veliparib. METHODS:TMZ was given once daily and veliparib twice daily for 5 days every 28 days. Veliparib concentrations and poly(ADP-ribose) (PAR) levels in PBMCs were measured on days 1 and 4. Analysis of pharmacokinetic and PBMC PAR levels were performed twice during study conduct to rationally guide dose modifications and to determine biologically optimal MTD/RP2D. RESULTS: Twenty-nine evaluable patients were enrolled. Myelosuppression (grade 4 neutropenia and thrombocytopenia) were dose limiting. The RP2Ds are veliparib 25 mg/m(2) b.i.d. and TMZ 135 mg/m(2)/d. Only 2 out of 12 patients treated at RP2Ds experienced dose-limiting toxicities. Although no objective response was observed, 4 patients had stable disease >6 months in duration, including 1 with glioblastoma multiforme and 1 with ependymoma. At the RP2D of veliparib, pediatric pharmacokinetic parameters were similar to those in adults. CONCLUSIONS:Veliparib and TMZ at the RP2D were well tolerated in children with recurrent brain tumors. A phase I/II trial to evaluate the tolerability and efficacy of veliparib, TMZ, and radiation in children with newly diagnosed brainstem gliomas is in progress.
Authors: J M de Murcia; C Niedergang; C Trucco; M Ricoul; B Dutrillaux; M Mark; F J Oliver; M Masson; A Dierich; M LeMeur; C Walztinger; P Chambon; G de Murcia Journal: Proc Natl Acad Sci U S A Date: 1997-07-08 Impact factor: 11.205
Authors: L S Lashford; P Thiesse; A Jouvet; T Jaspan; D Couanet; P D Griffiths; F Doz; J Ironside; K Robson; R Hobson; M Dugan; A D J Pearson; G Vassal; D Frappaz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: S Baruchel; M Diezi; D Hargrave; D Stempak; J Gammon; A Moghrabi; M J Coppes; C V Fernandez; E Bouffet Journal: Eur J Cancer Date: 2006-08-08 Impact factor: 9.162
Authors: T Ruscetti; B E Lehnert; J Halbrook; H Le Trong; M F Hoekstra; D J Chen; S R Peterson Journal: J Biol Chem Date: 1998-06-05 Impact factor: 5.157
Authors: Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Anthony Chalmers; Peter Johnston; Mick Woodcock; Michael Joiner; Brian Marples Journal: Int J Radiat Oncol Biol Phys Date: 2004-02-01 Impact factor: 7.038
Authors: Jeffrey M Albert; Carolyn Cao; Kwang Woon Kim; Christopher D Willey; Ling Geng; Dakai Xiao; Hong Wang; Alan Sandler; David H Johnson; Alexander D Colevas; Jennifer Low; Mace L Rothenberg; Bo Lu Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Elizabeth Stewart; Ross Goshorn; Cori Bradley; Lyra M Griffiths; Claudia Benavente; Nathaniel R Twarog; Gregory M Miller; William Caufield; Burgess B Freeman; Armita Bahrami; Alberto Pappo; Jianrong Wu; Amos Loh; Åsa Karlström; Chris Calabrese; Brittney Gordon; Lyudmila Tsurkan; M Jason Hatfield; Philip M Potter; Scott E Snyder; Suresh Thiagarajan; Abbas Shirinifard; Andras Sablauer; Anang A Shelat; Michael A Dyer Journal: Cell Rep Date: 2014-10-23 Impact factor: 9.423
Authors: Patricia A Baxter; Jack M Su; Arzu Onar-Thomas; Catherine A Billups; Xiao-Nan Li; Tina Young Poussaint; Edward R Smith; Patrick Thompson; Adekunle Adesina; Pete Ansell; Vincent Giranda; Arnold Paulino; Lindsey Kilburn; Ibrahim Quaddoumi; Alberto Broniscer; Susan M Blaney; Ira J Dunkel; Maryam Fouladi Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Sani H Kizilbash; Shiv K Gupta; Kenneth Chang; Ryo Kawashima; Karen E Parrish; Brett L Carlson; Katrina K Bakken; Ann C Mladek; Mark A Schroeder; Paul A Decker; Gaspar J Kitange; Yuqiao Shen; Ying Feng; Andrew A Protter; William F Elmquist; Jann N Sarkaria Journal: Mol Cancer Ther Date: 2017-09-25 Impact factor: 6.261
Authors: Steven T Sizemore; Rahman Mohammad; Gina M Sizemore; Somaira Nowsheen; Hao Yu; Michael C Ostrowski; Arnab Chakravarti; Fen Xia Journal: Mol Cancer Res Date: 2018-03-28 Impact factor: 5.852
Authors: Taofeek K Owonikoko; Suzanne E Dahlberg; Saad A Khan; David E Gerber; Jonathan Dowell; Rebecca A Moss; Chandra P Belani; Christine L Hann; Charu Aggarwal; Suresh S Ramalingam Journal: Lung Cancer Date: 2015-05-08 Impact factor: 5.705
Authors: Shiv K Gupta; Sani H Kizilbash; Brett L Carlson; Ann C Mladek; Felix Boakye-Agyeman; Katrina K Bakken; Jenny L Pokorny; Mark A Schroeder; Paul A Decker; Ling Cen; Jeanette E Eckel-Passow; Gobinda Sarkar; Karla V Ballman; Joel M Reid; Robert B Jenkins; Roeland G Verhaak; Erik P Sulman; Gaspar J Kitange; Jann N Sarkaria Journal: J Natl Cancer Inst Date: 2015-11-27 Impact factor: 13.506
Authors: Parker L Sulkowski; Christopher D Corso; Nathaniel D Robinson; Susan E Scanlon; Karin R Purshouse; Hanwen Bai; Yanfeng Liu; Ranjini K Sundaram; Denise C Hegan; Nathan R Fons; Gregory A Breuer; Yuanbin Song; Ketu Mishra-Gorur; Henk M De Feyter; Robin A de Graaf; Yulia V Surovtseva; Maureen Kachman; Stephanie Halene; Murat Günel; Peter M Glazer; Ranjit S Bindra Journal: Sci Transl Med Date: 2017-02-01 Impact factor: 19.319